肝纤维化的基因治疗研究进展

Research progress in gene therapy of liver cirrhosis

肝纤维化是各种慢性肝病发展至肝硬化的必经阶段,以纤维组织大量增生和肝小叶结构无序化为特征。近年来随着分子生物学的发展,肝纤维化的分子机制逐渐得以阐明,从而使肝纤维化的基因治疗成为可能,肝纤维化的基因治疗主要起到阻止纤维化发展、刺激肝细胞再生和肝组织结构重建三方面的作用。目前,常用的方法一般是通过抑制肝星状细胞(HSC)的活化,抑制HSC的增殖,及对HSC的靶向治疗等,达到延缓和治愈肝纤维化的目的。

Liver fibrosis is the imperative process of all kinds of chronic liver disease transform to liver cirrhosis, which is characterized by disorganization of normal hepatic structure of regenerative nodules and hyperplasia of fibrotic tissues. In recent years ,with the development of molecular biology ,the molecular mechanisms underlying liver fibrosis has been revealed more and more ,which makes the therapy at the gene level possible. The ideal strategy for the treatment of liver fibrosis should include the prevention of fibrogenesis , stimulation of hepatocyte proliferation and reorganization of the liver architecture. Re cently,several gene therapy approaches for treatment of liver fibrosis are inhibition the activation of hepatic stellate cell, the proliferation of hepatic stellate cell and targeted therapy of hepatic stellate cell, then delay and cure the liver fibrosis.